Cloud Hosting

The global Lifesciences Data Mining and Visualization market is anticipated to rise at a considerable rate during the forecast period, between 2021 and 2026. In 2021, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Global Lifesciences Data Mining and Visualization Market 2021 research report includes an outline of the business with industrial chain structure, applications, and prominent insights. Additionally, it provides details regarding the global market consisting of vital locales, their improvement techniques, focused scene investigation, and patterns of advancements. State-of-the-art plans and approaches are observed just as assembling cost structures and procedures are dissected likewise. Lifesciences Data Mining and Visualization Market report further mentions the gross productivity, income, value, cost, market figures, as well as trade utilities or imports.

Get a Sample PDF of the report with aMinimum 15% discount @ https://www.in4research.com/sample-request/21930

List of TOP KEY PLAYERS in Lifesciences Data Mining and Visualization Market Report is

The Lifesciences Data Mining and Visualization Market report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Lifesciences Data Mining and Visualization industry. This Lifesciences Data Mining and Visualization market report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins. For each manufacturer covered, this report analyzes their Lifesciences Data Mining and Visualization manufacturing sites, capacity, production, ex-factory price, revenue, and market share in the global Lifesciences Data Mining and Visualization market.

Based on product, each type primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications including

Major regions covered in the report:

Ask For Customization https://www.in4research.com/customization/21930

The Global Lifesciences Data Mining and Visualization market 2021 research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Global Lifesciences Data Mining and Visualization Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

The Lifesciences Data Mining and Visualization market report also tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. Global Lifesciences Data Mining and Visualization Market Size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries.

Major Points from Table of Contents:

1Lifesciences Data Mining and Visualization Market ReportOverview

2MarketPerspective

3CompetitiveLandscapebyManufacturers

4Global Lifesciences Data Mining and Visualization MarketSizebyType4.1Global HistoricMarketReviewbyType(2016-2021)4.2Global MarketEstimatesandForecastsbyType(2022-2026)

5Global Lifesciences Data Mining and Visualization MarketSizebyApplication5.1Global HistoricMarketReviewbyApplication(2016-2021)5.2GlobalMarketEstimatesandForecastsbyApplication(2022-2026)

6 GlobalLifesciences Data Mining and Visualization MarketSegmentation(RegionLevel)

7CompanyProfiles

8ValueChainandSalesChannelsAnalysis

9ResearchFindingsandConclusion

Continued

Ask for more discount packages for multiple reports @ https://www.in4research.com/contact

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Read more:

Lifesciences Data Mining and Visualization Market is Estimated to Expand at Significant CAGR Value From 2021-2026 |With COVID19 Impact The Almanian -...

Palantir, under CEO Alex Karp's leadership, is continuing its push into life sciences after a raft of pandemic-related government deals.

Drew Angerer/Getty Images

Alexander Karp, the CEO of Reddit favorite Palantir, was the highest paid chief executive of a public company last year, new survey data shows.

The CEO raked in $1.1 billion in total compensation in 2020, including $798 million in options, $296 million in restricted stock, and $1.1 million in salary, according to the company's 2020 annual proxy statement.

Data from Payscale shows the average Palantir employee makes $123,000 per year, meaning CEO Alex Karp's total compensation in 2020 was roughly 8,943 times greater than that of his average worker.

Palantir's co-founder and president Steven Cohen also received an epic pay package from the data mining company in 2020, receiving some $192 million, compared to $16.1 million in 2019, filings show.

In its proxy statement, Palantir said senior executive compensation is "designed to attract, retain, and motivate our leadership team in a highly competitive technology talent market while simultaneously aligning executive interests with those of our stockholders."

Palantir is a data mining powerhouse that was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003. The company generates roughly half of its revenue from government sources and recently inked contracts with the Centers for Disease Control and US Special Operations Command. Palantir also provides services to clients like IBM, Amazon, and Airbus.

CEO Alex Karp is known for his wild hair, brightly colored wardrobe, and for his time pursuing a Ph.D. in philosophy before starting Palantir. In 2021, Karp has been selling shares to lock in profits from his record compensation package. This year alone, the CEO has cashed out $309,906,961 worth of Palantir stock, according to SEC filings.

The second-highest-paid CEO in the world in 2020, DoorDash's Tony Xu, was awarded total compensation of $413 million in 2020, less than half of Karp's earnings, according to a comprehensive survey of the 200 highest-paid chief executives at public companies conducted for The New York Times by Equilar.

In 2020, CEOs in the Equilar survey earned an incredible 274 times the pay of their median employee and CEO pay jumped 14% year-over-year in 2020 amidst the pandemic.

Just 13 female CEOs made Equilar's list of the 200 top paid chief execs, with AMD's Dr. Lisa Su coming in as the highest-paid woman with a total compensation package of $40 million.

Excerpt from:

The CEO of Reddit darling Palantir was the highest paid chief executive of a public company last year - Markets Insider

The amyloid theory just wont die. In fact,by approving Biogen's new Alzheimer's disease drug, the FDA has justresurrected it for a long and healthy future.

This is great news for Biogen, but it will decimate Alzheimers research, faith in the agency and the healthcare budget for decades to come.

In an approval based on amyloid clearance, the FDA gave Biogen the benefit of the doubt in allowing it to market aducanumab, now Aduhelm, in Alzheimers, saying it doesnt need actual proof that it can help patients for many, many years.

Instead, the FDA saida surrogate endpoint, which substitutesa biomarker that might indicate efficacy for an actual clinical endpoint that demonstrates it directly,was good enough for a drug that could make Biogen $17 billion a year.

For the company, this endpoint was clearing amyloid, the sticky plaques that can accumulate in the brain thatpharma has spent years studying as the cause of Alzheimer's.

What all these tests have shownand this includes most of Biogens trialsis that clearing amyloid in Alzheimer's patients does not necessarily improve cognitive function nor lead to meaningful endpoints for patients or their families. Many drugs have cleared amyloidbut failed to produceany statistically significant clinical benefit and were then tossed into the trash.

This is, in fact, exactly what happened to aducanumab a few years back; after much hype, the drug failed to help Alzheimer's patients, and Biogen gave up, only to come back in 2019 after some data mining to find glimmers in a subpopulation.

Cognitive decline slowed in a statistically significant way in the subset of patients who received the highest dose of aducanumab, according tothe pharma's re-analysis. But aducanumabdid not show the same benefit when used at a lower dose in this trialand it didnt show a benefit at any dose in the other trial.

RELATED: Biogen's aducanumab crosses FDA finish line just in time to save its business

This was, Biogen reckoned, good enough, and it ran with this analysisto the FDA, which is under pressure to approve drugs in generaland especially in Alzheimer's after a 20-year drought.

The agency's own documents assessingthe drug, released late last year ahead of an expert advisory panel meeting, read like a press release from Biogen itself. But when the advisory committee met, it eviscerated the FDAdocuments and Biogens data.

The whole picture of the data are murky at best: Scott Emerson, M.D., Ph.D., a biostatistician at the University of Washington and an advisory committee panelist, said Biogens approach was akin to firing a shotgun at a barn and then painting a target around the bullet holes.

The FDA, however, went against its advisory committee, which is highly unusual, to approvethe med this week. And not just for a subpopulation, either, but pretty much for all Alzheimer's patients, and without the need for specific biomarkers.

There are more than 6 million Alzheimer's patients in the U.S.At a list priceof $56,000 for an average patient per year, before discounts, prescribing the infusion even to a quarter of these would cost more than $100 billion.

Biogens drug can cause serious side effects, which will need to be monitored. Around 40% of treated patients in Biogens late-stage trials developed brain swelling. Most didnt suffer symptoms, but they need regular brain scans to avoid complications.

Biogen will also have to do a new trial to prove its drug actually works, but that will take years, perhaps as many as nine. (Though the FDA has said it expects it more rapidly than that.)

RELATED: FDA's 'intellectually insulting' aducanumab decision opens up a regulatory foothold for leading competitors

We have already seen this situation with Sarepta Therapeutics and its equally controversial approval in 2016 for a new Duchenne muscular dystrophy drug. It used a surrogate endpointin this case, dystrophin increaseto win Exondys 51approval. A clinical benefit, however, was not found, as the FDA admitted.

Under the FDA's accelerated approval system, Sarepta got away with the surrogate endpoint, but the FDA required a follow-up trial. Five years down the line, and were still waiting for it. We couldsee history repeatitself for Biogen.

Both of my maternal grandparents died of Alzheimer's in their mid-80s after years of a slow decline. It is one of the most devastating diseases to watch, as it robs them of who they were, changes their personality and behavior and makes them forget who you are, erasing years of memories you thought were set in stone until it eventually kills them.

The care for Alzheimer's patients is frankly pathetic: There is one main drug, Aricept, which doesnt really work for most patients, with medical intervention focused on social care, or with home visits, and diagnosis done via a paper test.

The mainstays of my experience with the disease were trying to remind them who they are, keeping things consistent and not getting upset when they ask who you are. It felt like using a broom to sweep back the coming tide.

RELATED: FDA approval for aducanumab? Check. Soaring stocks for Biogen competitors? Yes, indeed

If theywere alive today, Aduhelm would not have helped them nor saved their lives. It would have added an extra financial burden on an already over-stretched system and possibly given them side effects that would have made things worse.

The FDA is, with this approval, peddling false hope, helping only Biogens C-suite and its investors, while opening the door for more amyloid drugs to be brushed off and put out anew, where the FDA via precedent would almost have to approve them if they clear amyloid well enough.

It's like arresting an innocent person on flimsy evidence they may have been involved in several murders, and then managing to get them convicted and thrown in jail; the local community are relieved that a serial killer is caught, and the police can notch up a success. The real murderer, however, remains at large, but no-one is looking for them anymore.

We dont understand the mechanics of Alzheimer's or how to stop it: Amyloid theory is one of the most tested areas in neuroscience, and it has come up snake eyes againand again and again. Yet, this decision opens the floodgates for more bad science.

Everyone is desperate for a working Alzheimer's drug, but this is not it. Now, instead of forcing companies to look elsewhere in their research and, hopefully, find better targets and curative approaches, we are stuck in the amyloid slow lane.

View post:

Editor's CornerThe FDA's decision on aducanumab will drag down innovation for years to come - FierceBiotech

Guwahati: Altogether Rs 12,500 crore of microfinance loans, comprising both principal and interest, are outstanding in Assam till March 31 last, minister Ashok Singhal said on Friday.

Twenty-six lakh customers with 45 lakh bank accounts have taken loans from 40 lenders, Singhal said at a press conference here.

Singhal said that 53 per cent of the outstanding amount of Rs 12,500 crore was lent by banks, 22 per cent by Non-Banking Finance Companies (NBFCs) and microfinance institutions, 26 per cent by small finance banks and 16 per cent by regular NBFCs.

The irrigation and urban development minister is heading a committee formed to assess the financial situation for fulfilling the BJPs election promise for waiving microfinance loans.

Chief Minister Himanta Biswa Sarma had decided to set up the panel in the first cabinet meeting on May 11 with Singhal as the chairman and principal secretaries of the finance and panchayat and rural development departments as members.

Also Read | Bhutan ensures irrigation water for Assam farmers

The chief minister had directed us to prepare a package to provide relief to maximum poor women who had taken loans and are facing immense miseries, Singhal said.

The committee has held three rounds of meetings with the stakeholders that include banks, NBFCs, small cooperatives, microfinance institutions and the RBI.

We had asked for the data which they provided but we realised that more data mining was required and it will be soon provided by the stakeholders. The discussions will continue and we expect to resolve the issue at the earliest, he said.

Certain criterion has to be followed according to RBI guidelines while giving loans to the borrowers but it is certain that norms have been flouted which has created problems for poor women borrowers, he said.

The basic norms to be followed is that a woman cannot be a member of more than one Self Help Groups (SHGs) and not more than two NBFCs should lend to the same borrower.

According to the data made available, 19.10 lakh customers have borrowed from one lender, 5.08 lakh from two lenders, 1.54 lakh from three lenders and 60,000 from more than three lenders.

The minister said that action will be taken against the lenders who have flouted norms within the legal framework as most of the women who had taken loans are not educated and are not aware of the terms and conditions.

He said that discussions are going on the relief provisions and only those loans will be considered which were taken before December 31, 2020.

He said those with a family income of Rs one lakh, paying income tax, owning four-wheelers or any other such guidelines set by the RBI will not be considered for the waiver of loans.

Visit link:

Rs 12,500 crore of microfinance loans outstanding in Assam - EastMojo

Reading Time: 5 minutes

Artificial Intelligence (AI) is changing how businesses used to work which is due to the high adoption of the technology in retail, financial, and technology industries. Business is advocating their efficiency and production rate increasing with artificial intelligence. Executives of organizations see artificial intelligence investment as a product with a high return on investment to the organization. Artificial intelligence is proving itself to be the backbone supporting the economic investments of the country.

In cybersecurity, Artificial Intelligence is the forefront fighter in the battle of saving organizations against hackers. According to MarketsAndMarkets report, artificial intelligence is projected to be a 38.2 billion USD industry by 2026. The prominent market value projection of artificial intelligence in cybersecurity paints a great picture. Yet artificial intelligence is like a double edge sword where hackers trying to gain access to your intelligent AI devices could cause more damage to your organization than the benefits you would have thought of getting from AI. Let us find out in this blog whether Artificial intelligence is threat proof from hackers or not.

Artificial intelligence is the branch of study which focuses on the question if a machine can think? Artificial intelligence tries to develop the capability of a machine to perform and think like a human. Machine are trained to make decisions like a human. This is done to shift the workload from human to machine, thus making peoples lives easier. The low prices of chipset and increase in computing speed of computer have made it possible for a man to have to talk back machine chatbox to self-driving car etc. in the world for an affordable price of the general public. According to finacesonline.com report, around 54% of organizations and leaders think AI tools play a significant role in boosting productivity in the organization. Artificial intelligence is changing industries into the smart industry.

Today every industry is adopting artificial intelligence at a very high rate. Artificial Intelligence is bringing the workload of workers and helping organizations increase productivity with the machine. Some of the applications of AI in the market are:

The sophistication of Artificial intelligence makes it the best technology helping organizations further their goals and ambitions. Yet, suppose the Artificial Intelligence technology installed in an organization is hacked. In that case, this could be hazardous and detrimental to the company and incur loss rather than profit. It is effortless to hack an AI machine by altering the dataset and confusing the machine to predict the wrong object instead of the real object. This might not sound so dangerous, but it is enough to cause disruptive incidents and cause loss of property and lives.

A self-autonomous car dataset being hacked could result in the car unable to identify the green signal from red; it could cause the vehicle to move into the oncoming traffic and cause accidents. The autonomous missiles misidentifying the friendly target for the real target could be disastrous. The security camera fed with the wrong database could mislead face detection to allow access to unauthorized persons in critical places like airports, border checks, etc. The severity of artificial intelligence being hacked create a dilemma in the use of the system. Companies need to invest in robust Artificial intelligence security at a similar pace as the speed of adoption of AI technology. A safe and secure environment for artificial intelligence is actively looked into by governments and organizations.

Its not only cybersecurity specialists using Artificial Intelligence to defend against ethical hacking, but hackers are also using artificial intelligence to conduct dangerous attacks. The robustness in artificial intelligence security is not of primary focus for organizations, as is the adoption of AI. This is a mistake, and there needs to be more focus on the secure and safe adoption of Artificial Intelligence to safeguard ourselves against hackers. Organizations and governments need to focus more on the security aspect of artificial intelligence technology and have a dedicated team of ethical hackers to strengthen their autonomous system and protect it from hackers malicious intent. Ethical hackers are trained cybersecurity experts well-versed in protecting AI technology, computer system, and networks against hackers.

For security enthusiasts reading the blog, to become an Ethical Hacker, EC-Councils Certified Ethical Hacker (CEH) certification is one the best certificates identified by industry leaders and governments worldwide. It is developed by security experts and designed to impart knowledge of becoming an Ethical hacker.

Become a Certified Ethical Hacker Today!

Do hackers use artificial intelligence?

Read more: Artificial Intelligence as Security Solution and Weaponization by Hackers

Will Artificial Intelligence stop hackers?

Read more: The Role of Artificial Intelligence in Ethical Hacking

Original post:

Is Artificial Intelligence (AI) prone to threats by which it can be hacked? - EC-Council Blog